Sutro Biopharma shareholders approve routine annual meeting matters, elect three directors

Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read

Key Changes

• low

  Shareholders elected Jane Chung, Connie Matsui, and James Panek as Class II directors for three-year terms expiring in 2029, with all three receiving majority support.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal 2026 with overwhelming approval (13.9M shares for vs. 501 against).

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved on advisory basis with strong shareholder support (11.3M for vs. 22K against), indicating satisfaction with current pay practices.

  Item 5.07 verify on EDGAR →